Position in NVS
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$668,410
+$31,443 QoQ
Shares Held
4,265
+2.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#767
of 1,603 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026ANCHYRA PARTNERS LLC holds $11,276,624 across 12 Drug Manufacturers - General names. NVS ranks #6 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,462 | $2,952,996 | |
| 2 | JNJ |
Johnson & Johnson
|
6,697 | $1,700,837 | |
| 3 | ABBV |
AbbVie Inc.
|
5,386 | $1,355,333 | |
| 4 | MRK |
Merck & Co., Inc.
|
9,746 | $1,252,361 | |
| 5 | AMGN |
Amgen Inc
|
3,094 | $1,120,399 | |
| 6 | NVS |
Novartis AG
This page
|
4,265 | $668,410 | |
| 7 | AZN |
Astrazeneca PLC
|
2,861 | $542,502 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
3,310 | $418,185 |
All Filings in NVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $668,410 | 4,265 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $636,967 | 4,170 | Shares | Sole | 2026-04-17 | |
| 2025-12-31 | $465,724 | 3,378 | Shares | Sole | 2026-01-29 | |
| No filing history on record for this holder in this stock. | ||||||